Innovations & Thérapeutiques en Oncologie
Volume 7, issue 1, January-February 2021
Volume 7, issue 1, January-February 2021
Éditorial/Editorial
ITO starts a new chapter with a bigger, rejuvenated team!
(p.3)
Yacine Merrouche
Free Access
Humeur/Opinion Column
Research project. Conception and production of genetically modified coronavirus aimed at individual lethal targeting
(p.4-6)
Jacques Robert, Jacques Bonnet
Free Access
Sélection et décryptage/Comments and Analysis
Comments and analysis
(p.7-23)
Patricia de Cremoux, Alexandre Bobard, Jacques Robert
Free Access
Innovations acquises/Established Innovations
Habits and therapeutic perceptions around HR+/ HER2– metastatic breast cancer in France, based on results from a national survey
(p.24-36)
Julien Péron, Thibaut Reverdy, Sylvie Giacchetti, Ophélie Cassuto, Tullia Devergé, Charlotte Bouyssou, Jean-Marc Ferrero, Elisabeth Luporsi, Florence Lerebours
Free Access
Innovations en cours/Ongoing Innovations
Use of melatonin in cancerology: the paradox
(p.37-44)
Matthieu Delaye, Timothée Lacombe, Christine Mateus, Sarah Dauchy
Free Access
Innovations futures/Future Innovations
DNA as a digital database. Something that affects us all!
(p.45-50)
Jacques Bonnet, Marthe Colotte, Delphine Coudy, Aurélie Luis, David Georges de Souza, Sophie Tuffet
Free Access
Les biotechs au coeur de l’innovation/Biotechnology and Innovation
A best in class TLR3 agonist soon to be clinically available. TL-532 as new therapeutic approach in immuno-oncology
(p.51-6)
Philippe Guillot-Chene
Free Access
Analyse d’ouvrage/Book Review
Nouvelles approches en pharmacologie oncologique
(p.57)
Jean-Louis Cazin
Free Access
Hommage/In Memoriam
Le président et la déléguée générale d’Unicancer rendent hommage à Christian Cailliot, ancien directeur de la recherche de la fédération
(p.58-9)
Unicancer
Free Access